Trial Profile
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2016
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary) ; Calcium acetate; Sevelamer
- Indications Hyperphosphataemia; Kidney disorders
- Focus Therapeutic Use
- 19 Dec 2014 New trial record